These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 7910865)

  • 21. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement.
    Hager WD; Davis BR; Riba A; Moye LA; Wun CC; Rouleau JL; Lamas GA; Pfeffer MA
    Am Heart J; 1998 Mar; 135(3):406-13. PubMed ID: 9506325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
    Vantrimpont P; Rouleau JL; Ciampi A; Harel F; de Champlain J; Bichet D; Moyé LA; Pfeffer M
    Eur Heart J; 1998 Oct; 19(10):1552-63. PubMed ID: 9820995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ventricular dysfunction and the risk of stroke after myocardial infarction.
    Loh E; Sutton MS; Wun CC; Rouleau JL; Flaker GC; Gottlieb SS; Lamas GA; Moyé LA; Goldhaber SZ; Pfeffer MA
    N Engl J Med; 1997 Jan; 336(4):251-7. PubMed ID: 8995087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
    Solomon SD; Zelenkofske S; McMurray JJ; Finn PV; Velazquez E; Ertl G; Harsanyi A; Rouleau JL; Maggioni A; Kober L; White H; Van de Werf F; Pieper K; Califf RM; Pfeffer MA;
    N Engl J Med; 2005 Jun; 352(25):2581-8. PubMed ID: 15972864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic effects of captopril on ischemia and dysfunction of the left ventricle after Q-wave and non-Q-wave myocardial infarction.
    Søgaard P; Nøgaard A; Gøtzsche CO; Ravkilde J; Thygesen K
    Am Heart J; 1994 Jan; 127(1):1-7. PubMed ID: 8273728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms involved in cardiac enlargement and congestive heart failure development after acute myocardial infarction.
    Kleber FX; Nussberger J; Niemöller L; Doering W
    Cardiology; 1992; 81(4-5):213-20. PubMed ID: 1301246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Lam CS; McEntegart M; Claggett B; Liu J; Skali H; Lewis E; Køber L; Rouleau J; Velazquez E; Califf R; McMurray JJ; Pfeffer M; Solomon S
    Eur J Heart Fail; 2015 Mar; 17(3):301-12. PubMed ID: 25655011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
    Thune JJ; Signorovitch JE; Kober L; McMurray JJ; Swedberg K; Rouleau J; Maggioni A; Velazquez E; Califf R; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2011 Feb; 13(2):148-53. PubMed ID: 21037250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The CAPITOL study (Captopril Post Infarction Tolerance). A trial of progressive titration of captopril after myocardial infarct with left ventricular dysfunction].
    Guéret P; Dubourg O; Vahanian A; Thuillez C; Bounhoure JP
    Arch Mal Coeur Vaiss; 1999 Apr; 92(4):395-403. PubMed ID: 10326147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
    Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
    Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmyocardial infarction patients: experience from the SAVE trial.
    Connors KF; Lamas GA
    Am J Crit Care; 1995 Jan; 4(1):23-8. PubMed ID: 7894551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics, left and right ventricular ejection fraction, and long-term prognosis in patients with non-insulin-dependent diabetes surviving an acute myocardial infarction.
    Melchior T; Gadsbøll N; Hildebrandt P; Køber L; Torp-Pedersen C
    Diabet Med; 1996 May; 13(5):450-6. PubMed ID: 8737027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
    ; Yusuf S; Pitt B; Davis CE; Hood WB; Cohn JN
    N Engl J Med; 1992 Sep; 327(10):685-91. PubMed ID: 1463530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction.
    Sharpe N; Murphy J; Smith H; Hannan S
    Eur Heart J; 1990 Apr; 11 Suppl B():147-56. PubMed ID: 2142081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction.
    Søgaard P; Gøtzsche CO; Ravkilde J; Thygesen K
    Circulation; 1993 Apr; 87(4):1093-9. PubMed ID: 8462137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart failure with preserved left ventricular ejection fraction in patients with acute myocardial infarction.
    Antonelli L; Katz M; Bacal F; Makdisse MR; Correa AG; Pereira C; Franken M; Fava AN; Serrano Junior CV; Pesaro AE
    Arq Bras Cardiol; 2015 Aug; 105(2):145-50. PubMed ID: 26039659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.